{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:28:43Z","timestamp":1761611323621},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,3,4]],"date-time":"2013-03-04T00:00:00Z","timestamp":1362355200000},"content-version":"vor","delay-in-days":62,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label \/><jats:p>A new topical fixed\u2010dose combination product containing clindamycin (1%, formulated as 1.2% clindamycin phosphate, CLNP 1.2%) with low strength (3%) benzoyl peroxide (BPO) in a methylparaben\u2010free gel vehicle (CLNP 1.2%\u2013BPO 3%\u2010MPF) has been developed for the treatment of acne. The objective of this study was to determine the relative bioavailability of clindamycin and clindamycin sulfoxide from CLNP 1.2%\u2013BPO 3%\u2010MPF compared with clindamycin phosphate 1.2%\u2010BPO 5% in a methylparaben\u2010preserved gel vehicle (CLNP 1.2%\u2013BPO 5%\u2010MP) and clindamycin phosphate 1.2%\u2013BPO 5% in a methylparaben\u2010free gel vehicle (CLNP 1.2%\u2013BPO 5%\u2010MPF), and to determine whether exposure is affected by BPO concentration (3% vs. 5%) when applied topically. Seventy\u2010two subjects with moderate\u2013severe acne were randomized to receive CLNP 1.2%\u2010BPO 3%\u2010MPF, CLNP 1.2%\u2013BPO 5%\u2010MP, or CLNP 1.2%\u2013BPO 5%\u2010MPF in a 5\u2010day, open\u2010label, and parallel\u2010group study. C<jats:sub>max<\/jats:sub> and AUC values for clindamycin were highest for CLNP 1.2%\u2013BPO 5%\u2010MP, followed by CLNP 1.2%\u2013BPO 3%\u2010MPF and CLNP 1.2%\u2013BPO 5%\u2010MPF, but differences were not statistically significant. Systemic exposure to clindamycin and clindamycin sulfoxide was low and comparable between the formulations. Results indicate that differences in BPO concentration do not influence clindamycin bioavailability.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cpdd.7","type":"journal-article","created":{"date-parts":[[2013,3,5]],"date-time":"2013-03-05T01:53:27Z","timestamp":1362448407000},"page":"33-47","source":"Crossref","is-referenced-by-count":5,"title":["Bioavailability of Clindamycin From a New Clindamycin Phosphate 1.2%\u2013Benzoyl Peroxide 3% Combination Gel"],"prefix":"10.1002","volume":"2","author":[{"given":"Terry M.","family":"Jones","sequence":"first","affiliation":[{"name":"J&amp;S Studies Inc. College Station, TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacy","family":"Jasper","sequence":"additional","affiliation":[{"name":"Stiefel, a GSK company Research Triangle Park, NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra B.","family":"Ali\u00f3 S\u00e1enz","sequence":"additional","affiliation":[{"name":"Stiefel, a GSK company Research Triangle Park, NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,4]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"44","article-title":"A newonce\u2010daily, optimized, fixed combination of clindamycin phosphate 1.2% and low\u2010concentration benzoyl peroxide 2.5% gel for the treatment of moderate\u2010to\u2010severe acne","volume":"2","author":"Gold MH.","year":"2009","journal-title":"J Clin Aesthet Dermatol."},{"key":"e_1_2_8_3_1","first-page":"5","article-title":"Benzoyl peroxide: enhancing antibiotic efficacy in acne management","volume":"15","author":"Dutil M.","year":"2010","journal-title":"Skin Ther Lett."},{"key":"e_1_2_8_4_1","first-page":"736","article-title":"Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations","volume":"8","author":"Webster G","year":"2009","journal-title":"J Drugs Dermatol."},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2008.07.001"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1983.tb07682.x"},{"key":"e_1_2_8_7_1","first-page":"482","article-title":"Benzoyl peroxide development, pharmacology, formulation and clinical uses in topical fixed\u2010combinations","volume":"9","author":"Harper JC.","year":"2010","journal-title":"J Drugs Dermatol."},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1995.tb05014.x"},{"key":"e_1_2_8_9_1","first-page":"417","article-title":"Antibiotic\u2010resistant Propionibacterium acnes suppressed by a benzoyl peroxide cleanser 6%","volume":"82","author":"Leyden JJ","year":"2008","journal-title":"Cutis."},{"key":"e_1_2_8_10_1","first-page":"12","article-title":"Improving treatment outcomes: tolerability of a fixed\u2010combination clindamycin 1%\u2010benzoyl peroxide 5% hydrating gel as monotherapy or in combination with a retinoid","volume":"84","author":"Eichenfield L.","year":"2009","journal-title":"Cutis."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200102010-00006"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)70177-4"},{"key":"e_1_2_8_13_1","first-page":"165","article-title":"A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris","volume":"67","author":"Tschen EH","year":"2001","journal-title":"Cutis."},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1986.tb04534.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656560903277228"},{"key":"e_1_2_8_16_1","first-page":"265","article-title":"Comparison of 2 clindamycin 1%\u2010benzoyl peroxide 5% topical gels used once daily in the management of acne vulgaris","volume":"83","author":"Dhawan SS.","year":"2009","journal-title":"Cutis."},{"key":"e_1_2_8_17_1","first-page":"15","article-title":"A review of the anti\u2010inflammatory properties of clindamycin in the treatment of acne vulgaris","volume":"85","author":"Del Rosso JQ","year":"2010","journal-title":"Cutis."},{"key":"e_1_2_8_18_1","first-page":"634","article-title":"The development and optimization of a fixed combination of clindamycin and benzoyl peroxide aqueous gel","volume":"8","author":"Bucks D","year":"2009","journal-title":"J Drugs Dermatol."},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.06.040"},{"key":"e_1_2_8_20_1","first-page":"281","article-title":"The effect of vehicle formulation on acne medication tolerability","volume":"82","author":"Draelos ZD","year":"2008","journal-title":"Cutis."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.2310\/6620.2009.08097"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(82)70109-4"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.1998.tb00902.x"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2510100508"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200304070-00004"},{"key":"e_1_2_8_26_1","first-page":"27","article-title":"Anti\u2010inflammatory properties of clindamycin: a review of its use in the treatment of acne vulgaris","volume":"4","author":"Whitney KM","year":"2011","journal-title":"Clin Med Insights: Dermatol."},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(86)70153-9"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1983.tb02113.x"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(81)70004-5"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(83)70209-4"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpdd.7","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T20:21:20Z","timestamp":1697660480000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1002\/cpdd.7"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.7","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}